The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.
Genetic tests may help psychiatrists choose which drugs to start their patients on, the Wall Street Journal reports.
Assurex Health will use the MassArray system with its GeneSight Psychotropic pharmacogenetic test.
The deal, which included $225 million in upfront payments and up to $185 million in milestones, gives Myriad entry into the neuroscience space.
Despite the historical adoption and reimbursement challenges for PGx testing firms, Myriad said it would try to achieve value-based pricing for Assurex's GeneSight test.
The deal will grant Myriad entry into the neuroscience space, and will allow it to use Assurex's existing sales force to market its own mental health tests.
Investors included existing shareholders Sequoia Capital, Claremont Creek Ventures, Cincinnati Children’s Hospital Medical Center, and Mayo Clinic.
Luminex said its technology will enhance the processing speed and capacity of Assurex's tests.
The funds will go toward efforts to drive clinical adoption and further develop Assurex's GeneSight products.
AdvaMedDx, a division of the Advanced Medical Technology Association, announced the election of several new members to its board of directors.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.
NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.
Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.
A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.